Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03RIO
|
||||
| Former ID |
DCL000383
|
||||
| Drug Name |
GSK598809
|
||||
| Indication | Drug abuse [ICD9: 303-304; ICD10:F10-F19] | Phase 2 | [1] | ||
| Company |
GSK
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Dopaminergic synapse | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01188967) Effectiveness of GSK598809, a Selective D3 Antagonist, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Very Early Relapse to Smoking. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.